Literature DB >> 26511402

Novel TKI-resistant BCR-ABL1 gatekeeper residue mutations retain in vitro sensitivity to axitinib.

E A Lasater1, E S Massi1, A Stecula2, J Politi1, S K Tan1, C C Smith1, M Gunthorpe3, J P Holmes4, F Chehab3, A Sali2,5,6, N P Shah1,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26511402     DOI： 10.1038/leu.2015.303

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  16 in total

1.  Comprehensive analysis of kinase inhibitor selectivity.

Authors:  Mindy I Davis; Jeremy P Hunt; Sanna Herrgard; Pietro Ciceri; Lisa M Wodicka; Gabriel Pallares; Michael Hocker; Daniel K Treiber; Patrick P Zarrinkar
Journal:  Nat Biotechnol       Date:  2011-10-30       Impact factor: 54.908

2.  Acquisition of the novel ABL kinase domain mutation T315L in a relapsed Philadelphia-positive acute lymphoblastic leukemia patient.

Authors:  Gee Fung How; Martin C Müller; Lay Cheng Lim
Journal:  Leuk Res       Date:  2011-09-06       Impact factor: 3.156

3.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.

Authors:  Tea Pemovska; Eric Johnson; Mika Kontro; Gretchen A Repasky; Jeffrey Chen; Peter Wells; Ciarán N Cronin; Michele McTigue; Olli Kallioniemi; Kimmo Porkka; Brion W Murray; Krister Wennerberg
Journal:  Nature       Date:  2015-02-09       Impact factor: 49.962

4.  Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.

Authors:  Simona Soverini; Sabrina Colarossi; Alessandra Gnani; Gianantonio Rosti; Fausto Castagnetti; Angela Poerio; Ilaria Iacobucci; Marilina Amabile; Elisabetta Abruzzese; Ester Orlandi; Franca Radaelli; Fabrizio Ciccone; Mario Tiribelli; Roberto di Lorenzo; Clementina Caracciolo; Barbara Izzo; Fabrizio Pane; Giuseppe Saglio; Michele Baccarani; Giovanni Martinelli
Journal:  Clin Cancer Res       Date:  2006-12-15       Impact factor: 12.531

5.  BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia.

Authors:  Matthew S Zabriskie; Christopher A Eide; Srinivas K Tantravahi; Nadeem A Vellore; Johanna Estrada; Franck E Nicolini; Hanna J Khoury; Richard A Larson; Marina Konopleva; Jorge E Cortes; Hagop Kantarjian; Elias J Jabbour; Steven M Kornblau; Jeffrey H Lipton; Delphine Rea; Leif Stenke; Gisela Barbany; Thoralf Lange; Juan-Carlos Hernández-Boluda; Gert J Ossenkoppele; Richard D Press; Charles Chuah; Stuart L Goldberg; Meir Wetzler; Francois-Xavier Mahon; Gabriel Etienne; Michele Baccarani; Simona Soverini; Gianantonio Rosti; Philippe Rousselot; Ran Friedman; Marie Deininger; Kimberly R Reynolds; William L Heaton; Anna M Eiring; Anthony D Pomicter; Jamshid S Khorashad; Todd W Kelley; Riccardo Baron; Brian J Druker; Michael W Deininger; Thomas O'Hare
Journal:  Cancer Cell       Date:  2014-08-14       Impact factor: 31.743

6.  Structural mechanism for STI-571 inhibition of abelson tyrosine kinase.

Authors:  T Schindler; W Bornmann; P Pellicena; W T Miller; B Clarkson; J Kuriyan
Journal:  Science       Date:  2000-09-15       Impact factor: 47.728

7.  The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants.

Authors:  John S Tokarski; John A Newitt; Chieh Ying J Chang; Janet D Cheng; Michael Wittekind; Susan E Kiefer; Kevin Kish; Francis Y F Lee; Robert Borzillerri; Louis J Lombardo; Dianlin Xie; Yaqun Zhang; Herbert E Klei
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

Authors:  Sara Redaelli; Luca Mologni; Roberta Rostagno; Rocco Piazza; Vera Magistroni; Monica Ceccon; Michela Viltadi; Daniel Flynn; Carlo Gambacorti-Passerini
Journal:  Am J Hematol       Date:  2012-10-09       Impact factor: 10.047

9.  High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib.

Authors:  Haifa-Kathrin Al-Ali; Michael Charles Heinrich; Thoralf Lange; Rainer Krahl; Matthias Mueller; Christel Müller; Dietger Niederwieser; Brian James Druker; Michael Werner Nikolaus Deininger
Journal:  Hematol J       Date:  2004

10.  Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency.

Authors:  Neil P Shah; Brian J Skaggs; Susan Branford; Timothy P Hughes; John M Nicoll; Ronald L Paquette; Charles L Sawyers
Journal:  J Clin Invest       Date:  2007-09       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.